The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials - PubMed (original) (raw)
Review
. 2012 May;69(5):1213-20.
doi: 10.1007/s00280-012-1828-8. Epub 2012 Jan 24.
Affiliations
- PMID: 22271210
- DOI: 10.1007/s00280-012-1828-8
Review
The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials
Ye-min Wang et al. Cancer Chemother Pharmacol. 2012 May.
Abstract
Background: Recently, melatonin has been associated with cancer both in vitro and in vivo. However, the value of melatonin in the treatment of cancer remains disputable. Hence, we performed a systematic review of randomized controlled trials (RCTs) of melatonin in solid tumor cancer patients and observed its effect on tumor remission, 1-year survival, and side effects due to radiochemotherapy.
Methods: An electronic search was conducted using the databases Pubmed, Medline, EMBASE, Cochrane library, and CNKI, from inception to November 2011. Trials using melatonin as adjunct treatment concurrent with chemotherapy or radiotherapy for cancer were included. Pooled relative risk (RR) for the tumor remission, 1-year survival, and radiochemotherapy-related side effects were calculated using the software Revman 5.0.
Results: The search strategy identified 8 eligible RCTs (n = 761), all of which studied solid tumor cancers. The dosage of melatonin used in the 8 included RCTs was 20 mg orally, once a day. Melatonin significantly improved the complete and partial remission (16.5 vs. 32.6%; RR = 1.95, 95% CI, 1.49-2.54; P < 0.00001) as well as 1-year survival rate (28.4 vs. 52.2%; RR = 1.90; 95% CI, 1.28-2.83; P = 0.001), and dramatically decreased radiochemotherapy-related side effects including thrombocytopenia (19.7 vs. 2.2%; RR = 0.13; 95% CI, 0.06-0.28; P < 0.00001), neurotoxicity (15.2 vs. 2.5%; RR = 0.19; 95% CI, 0.09-0.40; P < 0.0001), and fatigue (49.1 vs. 17.2%; RR = 0.37; 95% CI, 0.28-0.48; P < 0.00001). Effects were consistent across different types of cancer. No severe adverse events were reported.
Conclusions: Melatonin as an adjuvant therapy for cancer led to substantial improvements in tumor remission, 1-year survival, and alleviation of radiochemotherapy-related side effects.
Similar articles
- Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials.
Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ, Mills E. Seely D, et al. Integr Cancer Ther. 2012 Dec;11(4):293-303. doi: 10.1177/1534735411425484. Epub 2011 Oct 21. Integr Cancer Ther. 2012. PMID: 22019490 Review. - Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis.
Mills E, Wu P, Seely D, Guyatt G. Mills E, et al. J Pineal Res. 2005 Nov;39(4):360-6. doi: 10.1111/j.1600-079X.2005.00258.x. J Pineal Res. 2005. PMID: 16207291 Review. - Ganoderma lucidum (Reishi mushroom) for cancer treatment.
Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Jin X, et al. Cochrane Database Syst Rev. 2012 Jun 13;(6):CD007731. doi: 10.1002/14651858.CD007731.pub2. Cochrane Database Syst Rev. 2012. PMID: 22696372 Updated. Review. - Maintenance chemotherapy for ovarian cancer.
Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie HY, Wang X, Zou J, Han X, Feng D. Mei L, et al. Cochrane Database Syst Rev. 2010 Sep 8;(9):CD007414. doi: 10.1002/14651858.CD007414.pub2. Cochrane Database Syst Rev. 2010. PMID: 20824860 Updated. Review. - Bisphosphonates for breast cancer.
Pavlakis N, Stockler M. Pavlakis N, et al. Cochrane Database Syst Rev. 2002;(1):CD003474. doi: 10.1002/14651858.CD003474. Cochrane Database Syst Rev. 2002. PMID: 11869664 Updated. Review.
Cited by
- The Effect of Melatonin Supplementation on Cancer-Related Fatigue during Chemotherapy Treatment of Breast Cancer Patients: A Double-Blind, Randomized Controlled Study.
Nimee F, Gioxari A, Papandreou P, Amerikanou C, Karageorgopoulou S, Kaliora AC, Skouroliakou M. Nimee F, et al. Cancers (Basel). 2024 Feb 16;16(4):802. doi: 10.3390/cancers16040802. Cancers (Basel). 2024. PMID: 38398193 Free PMC article. - Melatonin May Increase Anticancer Potential of Pleiotropic Drugs.
Bojková B, Kubatka P, Qaradakhi T, Zulli A, Kajo K. Bojková B, et al. Int J Mol Sci. 2018 Dec 6;19(12):3910. doi: 10.3390/ijms19123910. Int J Mol Sci. 2018. PMID: 30563247 Free PMC article. Review. - Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial.
Palmer ACS, Zortea M, Souza A, Santos V, Biazús JV, Torres ILS, Fregni F, Caumo W. Palmer ACS, et al. PLoS One. 2020 Apr 17;15(4):e0231379. doi: 10.1371/journal.pone.0231379. eCollection 2020. PLoS One. 2020. PMID: 32302347 Free PMC article. Clinical Trial. - Immune-pineal axis - acute inflammatory responses coordinate melatonin synthesis by pinealocytes and phagocytes.
Markus RP, Fernandes PA, Kinker GS, da Silveira Cruz-Machado S, Marçola M. Markus RP, et al. Br J Pharmacol. 2018 Aug;175(16):3239-3250. doi: 10.1111/bph.14083. Epub 2017 Dec 15. Br J Pharmacol. 2018. PMID: 29105727 Free PMC article. Review. - The Time for Chronotherapy in Radiation Oncology.
Bermúdez-Guzmán L, Blanco-Saborío A, Ramírez-Zamora J, Lovo E. Bermúdez-Guzmán L, et al. Front Oncol. 2021 May 11;11:687672. doi: 10.3389/fonc.2021.687672. eCollection 2021. Front Oncol. 2021. PMID: 34046365 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources